Long-Acting Injectable Aripiprazole Approved for Schizophrenia

April 14, 2016 · Posted in Current Treatments · Comment 

injection for schizophreniaIn October, the US Food and Drug Administration (FDA) approved an injectable, long-acting version of the atypical antipsychotic aripiprazole for the treatment of adults with schizophrenia.

The long-acting aripiprazole is administered every 4 to 6 weeks as an injection in the arm or buttocks. The company announced that it would begin releasing the drug immediately. The drug preparation for maintenance treatment is named Maintena while the preparation for acute treatment is named Aristada.